Therapeutic Perspectives in Lymphoma Management: Current Considerations With Novel Bispecific Antibodies
Released On
December 27, 2022
Expires On
December 27, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology
Topic(s)
Lymphoma, Non-Hodgkin's Lymphoma (NHL)
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Med Learning Group and Ultimate Medical Academy/Complete Conference Management (CCM).
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The STRIVE Initiative is intended to meet the educational needs of medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.
Program Overview
STRIVE aims to create an initiative that HCPs can access to better define novel targets in the management of B-cell lymphomas, including bispecific antibodies and combinations under evaluation; summarize outcomes of key trials in B-cell lymphoma management, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma; and lastly to evaluate potential adverse events associated with novel therapies and best practices for management of adverse events in a multidisciplinary manner.
Learning Objectives
Upon the completion of this program, attendees should be able to:
- Define novel targets in the management of B-cell lymphomas, including bispecific antibodies and combinations under evaluation
- Summarize outcomes of key trials in B-cell lymphoma management, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma
- Evaluate potential adverse events associated with novel therapies and best practices for management of adverse events in a multidisciplinary manner
Faculty
Ken H. Young, MD, PhD
Professor
Duke University Medical Center
Duke Cancer Center
Durham, NC
Physician Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Credit Designation
Purpose: This program would be beneficial for nurses involved in the care of patients with Non-Hodgkin's Lymphoma (NHL). CNE Credits: 1.0 ANCC Contact Hour.
CNE Accreditation Statement
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosures of Conflicts of Interest
Ken H. Young, MD, PhD, has received research support from High-Throughput Genomics and EUSA Pharma. He serves on the scientific advisory board for Precision Genomic Testing, Union Precision Diagnostics, and Pregene Therapeutics.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Vaidehee S. Deshpande, PhD, Medical Director for Med Learning Group has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Method of Participation
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com.
Americans with Disabilities Act
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/"
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.